References
- O’Donnell J, Gladden RM, Mattson CL, Hunter CT, Davis NL. Vital signs: characteristics of drug overdose deaths involving opioids and stimulants - 24 states and the District of Columbia, January-June 2019. MMWR Morb Mortal Wkly Rep. 2020;69(35):1189–1197.
- Leshner AI, Mancher M, eds. Medications for Opioid Use Disorder save Lives. Washington, DC: National Academies Press; 2019.
- Fornili KS, Fogger SA. Nurse practitioner prescriptive authority for buprenorphine: from DATA 2000 to CARA 2016. J Addict Nurs. 2017;28(1):43–48.
- Manz J, Purrington K. Government Eliminates Waiver Requirement for Doctors Prescribing the Addiction Treatment Medication Buprenorphine. National Academy for State Health Policy Web site. https://www.nashp.org/government-eliminates-waiver-requirement-for-doctors-prescribing-the-addiction-treatment-medication-buprenorphine/. Published 2021. Accessed January 18, 2021.
- Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2020.
- NCQA. Quality ID #468 (NQF 3175): continuity of pharmacotherapy for opioid use disorder (OUD). https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2019_Measure_468_MIPSCQM.pdf. Published 2020. Accessed January 2, 2020.
- Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.
- Saloner B, Daubresse M, Caleb Alexander G. Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population. Med Care. 2017;55(7):669–676.
- Yarbrough CR, Abraham AJ, Adams GB. Relationship of county opioid epidemic severity to changes in access to substance use disorder treatment, 2009-2017. Psychiatr Serv. 2020;71(1):12–20.
- Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update: distribution of providers with a DEA waiver. J Rural Health. 2019;35(1):108–112.
- Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse. 2020;46(3):273–288.
- McBain RK, Dick A, Sorbero M, Stein BD. Growth and distribution of buprenorphine-waivered providers in the United States, 2007-2017. Ann Intern Med. 2020;172(7):504–506.
- Langabeer JR, Stotts AL, Cortez A, Tortolero G, Champagne-Langabeer T. Geographic proximity to buprenorphine treatment providers in the U.S. Drug Alcohol Depend. 2020;213:108131.
- Amiri S, McDonell MG, Denney JT, Buchwald D, Amram O. Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: a US nationwide small area analysis. Value Health. 2021;24(2):188–195.
- Jones CW, Christman Z, Smith CM, et al. Comparison between buprenorphine provider availability and opioid deaths among US counties. J Subst Abuse Treat. 2018;93:19–25.
- Beardsley K, Wish ED, Fitzelle DB, O’Grady K, Arria AM. Distance traveled to outpatient drug treatment and client retention. J Subst Abuse Treat. 2003;25(4):279–285.
- Schmitt SK, Phibbs CS, Piette JD. The influence of distance on utilization of outpatient mental health aftercare following inpatient substance abuse treatment. Addict Behav. 2003;28(6):1183–1192.
- Amiri S, Lutz R, Socías ME, McDonell MG, Roll JM, Amram O. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. J Subst Abuse Treat. 2018;93:26–30.
- Amiri S, Lutz RB, McDonell MG, Roll JM, Amram O. Spatial access to opioid treatment program and alcohol and cannabis outlets: analysis of missed doses of methadone during the first, second, and third 90 days of treatment. Am J Drug Alcohol Abuse. 2020;46(1):78–87.
- Cole ES, DiDomenico E, Cochran G, et al. The role of primary care in improving access to medication-assisted treatment for rural medicaid enrollees with opioid use disorder. J Gen Intern Med. 2019;34(6):936–943.
- Kleinman RA. Comparison of driving times to opioid treatment programs and pharmacies in the US. JAMA Psychiatry. 2020;77(11):1163–1171.
- Hancock C, Mennenga H, King N, Andrilla CHA, Larson EH, Schou P. Treating the rural opioid epidemic. https://www.ruralhealthweb.org/NRHA/media/Emerge_NRHA/Advocacy/Policy%20documents/2019-NRHA-Policy-Document-Treating-the-Rural-Opioid-Epidemic.pdf. Published 2019. Accessed July 22, 2021.
- Cyr ME, Etchin AG, Guthrie BJ, Benneyan JC. Access to specialty healthcare in urban versus rural US populations: a systematic literature review. BMC Health Serv Res. 2019;19(1):974.
- Buzza C, Ono SS, Turvey C, et al. Distance is relative: unpacking a principal barrier in rural healthcare. J Gen Intern Med. 2011;26(S2):648–654.
- Stein BD, Saloner B, Schuler MS, Gurvey J, Sorbero M, Gordon AJ. Concentration of patient care among buprenorphine-prescribing clinicians in the US. JAMA. 2021;325(21):2206–2208.
- Centers for Disease Control and Prevention. Drug overdose mortality by state. https://www.cdc.gov/nchs/pressroom/sosmap/drug_poisoning_mortality/drug_poisoning.htm. Published 2020. Accessed December 15, 2020.
- Iowa State University Community Indicators Program. Urban percentage of the population for states, historical. https://www.icip.iastate.edu/tables/population/urban-pct-states. Published 2020. Accessed December 15, 2020.
- West Virginia Department of Health. DHHR’s Medicaid program to expand substance use treatment and services. https://dhhr.wv.gov/News/2017/Pages/DHHR%E2%80%99s-Medicaid-Program-to-Expand-Substance-Use-Treatment-and-Services.aspx. Published 2017. Accessed December 16, 2020.
- Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211–1212.
- Beetham T, Saloner B, Wakeman SE, Gaye M, Barnett ML. Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study. Ann Intern Med. 2019;171(1):1–9.
- US Census Bureau. West Virginia: basic information. https://www.census.gov/geographies/reference-files/2010/geo/state-local-geo-guides-2010/west-virginia.html. Published 2018. Accessed November 25, 2020.
- Saloner B, Landis R, Stein BD, Barry CL. The affordable care act in the heart of the opioid crisis: evidence from West Virginia. Health Aff. 2019;38(4):633–642.
- US Census Bureau. ZIP code tabulation areas (ZCTAs). https://www.census.gov/programs-surveys/geography/guidance/geo-areas/zctas.html. Published 2021. Accessed July 14, 2021.
- Google Maps Developers. Google maps platform: distance matrix API. https://developers.google.com/maps/documentation/distance-matrix/overview?hl=en. Published 2021. Accessed July 14, 2021.
- Electronic Code of Federal Regulations. Payment for durable medical equipment and prosthetic and orthotic devices. https://www.law.cornell.edu/cfr/text/42/414.202. Published 2014. Accessed October 1, 2021.
- HUD USPS ZIP Code Crosswalk Files. US Department of Housing and Urban Development; https://www.huduser.gov/portal/datasets/usps_crosswalk.html. Published 2021. Accessed July 14, 2021.
- Garnick DW, Horgan CM, Acevedo A, et al. Rural clients’ continuity into follow-up substance use disorder treatment: impacts of travel time, incentives, and alerts. J Rural Health. 2020;36(2):196–207.
- Thomas CP, Doyle E, Kreiner PW, et al. Prescribing patterns of buprenorphine waivered physicians. Drug Alcohol Depend. 2017;181:213–218.
- Duncan A, Anderman J, Deseran T, Reynolds I, Stein BD. Monthly patient volumes of buprenorphine-waivered clinicians in the US. JAMA Netw Open. 2020;3(8):e2014045.
- Patrick SW, Richards MR, Dupont WD, et al. Association of pregnancy and insurance status with treatment access for opioid use disorder. JAMA Netw Open. 2020;3(8):e2013456.
- Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115(9):1683–1694.
- Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013-2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):202–207.
- Drake C, Donohue JM, Nagy D, Mair C, Kraemer KL, Wallace DJ. Geographic access to buprenorphine prescribers for patients who use public transit. J Subst Abuse Treat. 2020;117:108093.
- Barnett ML, Lee D, Frank RG. In rural areas, buprenorphine waiver adoption since 2017 driven by nurse practitioners and physician assistants. Health Aff. 2019;38(12):2048–2056.
- Hinde JM, Mark TL, Fuller L, Dey J, Hayes J. Increasing access to opioid use disorder treatment: assessing state policies and the evidence behind them. J Stud Alcohol Drugs. 2019;80(6):693–697.
- Ghertner R, Ali MM. Increases in providers with buprenorphine waivers in the United States from 2016 to 2019. Psychiatr Serv. 2020;71(9):971–971.
- Substance Abuse and Mental Health Services Administration. FAQs: Provision of Methadone and Buprenorphine for the Treatment of Opioid Use Disorder in the COVID-19 Emergency. Substance Abuse and Mental Health Services Administration Web site. https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf. Published 2020. Accessed July 22, 2021.
- Nguyen TD, Gupta S, Ziedan E, et al. Assessment of filled buprenorphine prescriptions for opioid use disorder during the coronavirus disease 2019 pandemic. JAMA Intern Med. 2021;181(4):562.
- Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I, Barnett ML. Trends in outpatient care delivery and telemedicine during the COVID-19 pandemic in the US. JAMA Intern Med. 2021;181(3):388–391.
- Uscher-Pines L, Sousa J, Raja P, Mehrotra A, Barnett M, Huskamp HA. Treatment of opioid use disorder during COVID-19: experiences of clinicians transitioning to telemedicine. J Subst Abuse Treat. 2020;118:108124.
- West Virginia Department of Health and Human Resources. Your Guide to Medicaid. Charleston, WV: Department of Health and Human Resources; 2019.